MedTrace Logo

Metabolomic Analysis of Systemic Sclerosis

NCT02298777 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2025-08-08

No results posted yet for this study

Summary

Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.

The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular lesions, by comparing the profiles of SSc beginners (\<3 years) to established forms (\> 3 years).

Secondary purposes:

* Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs
* Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy controls
* Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc patients

Conditions

  • Scleroderma (Limited and Diffuse)
  • Undifferentiated Connective Tissue Disease
  • Raynaud Disease
  • Vascular Disease
  • Healthy Control Subjects

Interventions

PROCEDURE

- Skin biopsy - Urine sample - Blood sample

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Chatelus Emmanuel, MD · Hôpitaux Universitaires de Strasbourg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2025-04-24
Completion
2025-04-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02298777 on ClinicalTrials.gov